Guide
Nicotinamide riboside (NR): liposomal, powder and liquid
Liposomal, powder and liquid nicotinamide riboside are all untested formats compared with the capsule-based research the NAD+ and safety data come from; here's what each format's label needs to state before a dose can be judged.
"Liposomal" nicotinamide riboside is NR packaged inside a lipid shell, marketed to improve absorption; no published human trial has tested whether it actually raises blood NAD+ more than a standard capsule. Loose powder and liquid drops are two other formats sold alongside it, and each carries its own dosing and quality questions that a capsule label answers more directly.
What is liposomal nicotinamide riboside?
"Liposomal" describes a delivery method, not the compound itself: NR is encased in tiny lipid (fat) spheres meant to help it cross the gut lining intact. The human trials that established NR raises blood NAD+ — including the first 2016 pharmacokinetics study and the largest 2019 safety trial, both covered in full on what is nicotinamide riboside? — used a standard oral capsule or tablet form of NR, not a liposomal product. No published study has measured whether a liposomal version changes how much reaches the bloodstream compared with those capsule-based trials.
Nicotinamide riboside powder and liquid
Loose NR powder and liquid drops are the same compound sold without a capsule shell. As with the liposomal question, no trial has tested either format against the capsule-based products used in the human research. A liquid product should state milligrams of nicotinamide riboside per drop or per milliliter, and a powder product should state milligrams per scoop or gram — without that figure stated clearly, it's hard to compare a serving against the 100-2,000 mg/day range covered in nicotinamide riboside dosage.
Combination products
Nicotinamide riboside is frequently sold blended with resveratrol or pterostilbene, both marketed as complementary longevity compounds. That matters for reading the research: a trial testing an NR-and-pterostilbene combination product found dose-dependent NAD+ increases and no serious adverse events, but a separate paper notes that same combination trial also found a dose- and time-dependent rise in LDL cholesterol — an effect not seen when NR was tested alone, without pterostilbene, in a different 8-week trial. If a product blends NR with another ingredient, the research on NR by itself doesn't necessarily describe what the blend does.
Questions people ask
What is liposomal nicotinamide riboside?
NR encased in a lipid shell to potentially improve absorption. No published human trial has tested whether it raises blood NAD+ more than a standard capsule.
Is liposomal nicotinamide riboside better?
There's no trial comparing it against a standard capsule, so "better absorbed" is a marketing claim without a published human trial behind it either way.
How to take liposomal nicotinamide riboside
Follow the specific product's label. There's no independent research-based dosing guide for the liposomal format specifically — compare its stated milligram amount against the 100-2,000 mg/day range tested in capsule-based trials.
Is liposomal nicotinamide riboside safe?
No dedicated safety trial has tested the liposomal format itself. NR taken in standard capsule form has been generally well tolerated in trials up to 2,000 mg/day for 12 weeks — see nicotinamide riboside side effects — but that data comes from capsules, not a liposomal, powder or liquid product.
Related reading
what is nicotinamide riboside?, how to choose a good nicotinamide riboside, and nicotinamide riboside dosage.
Sources
- Nicotinamide riboside is uniquely and orally bioavailable in mice and humans The first published human trial of nicotinamide riboside (2016) found single oral doses of 100–1,000 mg produced a dose-dependent rise in blood NAD+ in 12 healthy adults, and that NR behaves differently in the body than the other two forms of vitamin B3.
- Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults A 2019 randomized, placebo-controlled trial of 140 adults found nicotinamide riboside raised blood NAD+ dose-dependently at 100-1,000 mg/day over 8 weeks with no reports of flushing and no rise in LDL cholesterol or homocysteine, unlike the other forms of vitamin B3.
- Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD(+) levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study A 2017 trial of a nicotinamide-riboside-and-pterostilbene combination product in 120 older adults found dose-dependent NAD+ increases (about 40% and 90% at two doses) over 8 weeks with no serious adverse events — a combination-product result, not one isolating NR alone, and no clinical outcome beyond NAD+ was measured.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.